文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Jennings K, Jackson P G, Monaghan M, Jewitt D E

Br J Clin Pharmacol. 1978 Jan;5(1):13-8. doi: 10.1111/j.1365-2125.1978.tb01592.x.

A phosphodiesterase inhibitor, UK 14,275 (Pfizer) was administered intravenously to six patients with suspected coronary artery disease under-going diagnostic cardiac catheterisation to assess its inotropic activity. 2. Intracardiac haemodynamic measurements included pulmonary and systemic arterial pressure. Left ventricular end diastolic pressure and left ventricular dP/dtmax were also measured, in addition to cardiac output using the indocyanine green dye technique. 3. UK 14,275 resulted in a significant increase in LV dP/dtmax and cardiac output. 4. No chronotropic action was observed using this agent. 5. This agent may have potential therapeutic value in the management of cardiovascular failure associated with low cardiac output.

给6例疑似冠心病且正在接受诊断性心导管插入术的患者静脉注射磷酸二酯酶抑制剂UK 14,275（辉瑞公司生产），以评估其变力活性。2. 心内血流动力学测量包括肺和体动脉压。除了使用吲哚菁绿染料技术测量心输出量外，还测量了左心室舒张末期压力和左心室dP/dtmax。3. UK 14,275使左心室dP/dtmax和心输出量显著增加。4. 使用该药物未观察到变时作用。5. 该药物在治疗与低心输出量相关的心血管衰竭方面可能具有潜在的治疗价值。

Jennings K, Jackson P G, Monaghan M, Jewitt D E

Br J Clin Pharmacol. 1978 Jan;5(1):13-8. doi: 10.1111/j.1365-2125.1978.tb01592.x.

A phosphodiesterase inhibitor, UK 14,275 (Pfizer) was administered intravenously to six patients with suspected coronary artery disease under-going diagnostic cardiac catheterisation to assess its inotropic activity. 2. Intracardiac haemodynamic measurements included pulmonary and systemic arterial pressure. Left ventricular end diastolic pressure and left ventricular dP/dtmax were also measured, in addition to cardiac output using the indocyanine green dye technique. 3. UK 14,275 resulted in a significant increase in LV dP/dtmax and cardiac output. 4. No chronotropic action was observed using this agent. 5. This agent may have potential therapeutic value in the management of cardiovascular failure associated with low cardiac output.

给6例疑似冠心病且正在接受诊断性心导管插入术的患者静脉注射磷酸二酯酶抑制剂UK 14,275（辉瑞公司生产），以评估其变力活性。2. 心内血流动力学测量包括肺和体动脉压。除了使用吲哚菁绿染料技术测量心输出量外，还测量了左心室舒张末期压力和左心室dP/dtmax。3. UK 14,275使左心室dP/dtmax和心输出量显著增加。4. 使用该药物未观察到变时作用。5. 该药物在治疗与低心输出量相关的心血管衰竭方面可能具有潜在的治疗价值。